Sage Clinical Medicine & Research
Tumori Journal – Author's Insight: A phase 2 study of cabozantinib for advanced renal cell carcinoma after immune-checkpoint inhibitors: the BREAKPOINT trial
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:09:26
- More information
Informações:
Synopsis
In this podcast, Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial: a prospective, multicenter, single arm phase II trial evaluating efficacy and safety of cabozantinib for patients with metastatic renal cell carcinoma progressed after one line of treatment based on immune-checkpoints inhibitors.
